Pulmonary and cardiovascular effects of mefloquine methanesulfonate

Robert W. Caldwell, Clinton B. Nash

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Mefloquine methanesulfonate (WR-142, 490·CH3SO3H), a highly effective antimalarial agent, when infused at a dose rate of 1 mg/kg/ min for 20 min in the anesthetized dog, caused either little or no effect on the pulmonary and cardiovascular parameters measured during this drug infusion or in the following 3-hr observation period. However, dose rates of 2 and 3 mg/kg/min of mefloquine MS for 20 min did produce pulmonary and cardiovascular changes. The respiratory parameters which were observed to change were: (1) tidal volume, which fell during the drug infusion but then returned to control values during the remaining portion of the observation period; (2) respiratory rate, which rose during the drug infusion, but returned to control values; (3) dynamic airways resistance, which decreased during drug administration, but then rose above control values; (4) small gradual changes in blood pO2 and pCO2. The cardiovascular parameters observed to change were: (1) arterial blood pressure, which decreased during the drug infusion, but returned rapidly to control values; (2) cardiac contractile force, which diminished during the drug infusion and returned toward control values later in the observation period; (3) central venous pressure, which rose transiently during drug administration; (4) pulmonary artery pressure, which rose initially, but tended to decrease late in the observation period and returned to control values within a 24-hr period. The magnitude of the effects of mefloquine MS appeared to be more dependent on the dose rate of drug delivery than on the total dose delivered.

Original languageEnglish (US)
Pages (from-to)437-448
Number of pages12
JournalToxicology and Applied Pharmacology
Issue number3
StatePublished - Jun 1977
Externally publishedYes

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Pulmonary and cardiovascular effects of mefloquine methanesulfonate'. Together they form a unique fingerprint.

Cite this